Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $45.10 Average Price Target from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and twelve have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $45.10.

A number of research firms recently commented on AVTX. Bank of America started coverage on Avalo Therapeutics in a research note on Friday, June 12th. They issued a “buy” rating and a $35.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Leerink Partners began coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They set an “outperform” rating and a $38.00 price target for the company. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Finally, Wedbush dropped their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $19.23 on Tuesday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.40 and a beta of 0.78. Avalo Therapeutics has a twelve month low of $9.54 and a twelve month high of $24.27. The stock has a fifty day simple moving average of $19.12 and a 200 day simple moving average of $16.99.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Research analysts expect that Avalo Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,129 shares of company stock worth $59,680 over the last ninety days. 4.46% of the stock is owned by company insiders.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the business. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics during the third quarter worth approximately $143,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics in the first quarter worth approximately $174,000. California State Teachers Retirement System bought a new stake in Avalo Therapeutics in the second quarter worth approximately $196,000. Finally, Jump Financial LLC bought a new stake in Avalo Therapeutics in the fourth quarter worth approximately $238,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.